Literature DB >> 12973403

Antipsychotic medication and seizures: a review.

Dawson Hedges1, Kreg Jeppson, Paul Whitehead.   

Abstract

Both first-generation and second-generation antipsychotic medications can lower the seizure threshold, increasing the chances of seizure induction. This article reviews the published literature concerning the seizure-lowering effects of first- and second-generation antipsychotic medication. Unfortunately, rigorously controlled studies are relatively infrequent, and case reports form a large part of the available literature, limiting the confidence with which firm conclusions can be drawn. Of the first-generation antipsychotic medications, chlorpromazine appears to be associated with the greatest risk of seizure provocation, although other first-generation antipsychotics also lower seizure threshold. Conversely, molindone, haloperidol, fluphenazine, pimozide and trifluoperazine are associated with a lower risk of seizure induction. Clozapine is the second-generation antipsychotic most frequently associated with seizures, with risperidone appearing to confer a relatively low risk. Other factors such as history of seizure activity, concurrent use of other drugs that lower seizure threshold, rapid dose titration, slow drug metabolism, metabolic factors and drug-drug interactions appear to increase the chances of an antipsychotic medication inducing seizure activity. Copyright 2003 Prous Science. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12973403     DOI: 10.1358/dot.2003.39.7.799445

Source DB:  PubMed          Journal:  Drugs Today (Barc)        ISSN: 1699-3993            Impact factor:   2.245


  31 in total

Review 1.  [Polypharmacy and pain treatment].

Authors:  Markus Gosch; Birgit Böhmdorfer; Ursula Benvenuti-Falger; Peter Dovjak; Bernhard Iglseder; Monika Lechleitner; Ronald Otto; Regina E Roller; Ulrike Sommeregger
Journal:  Wien Med Wochenschr       Date:  2010-06

Review 2.  Practical considerations for the treatment of elderly patients with migraine.

Authors:  Paola Sarchielli; Maria Luisa Mancini; Paolo Calabresi
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

3.  Manifestation of multiple sclerosis with paranoid-hallucinatory psychosis.

Authors:  Jens Reimer; Volkmar Aderhold; Martin Lambert; Christian Haasen
Journal:  J Neurol       Date:  2006-02-03       Impact factor: 4.849

Review 4.  Multidisciplinary assessment and treatment of self-injurious behavior in autism spectrum disorder and intellectual disability: integration of psychological and biological theory and approach.

Authors:  Noha F Minshawi; Sarah Hurwitz; Danielle Morriss; Christopher J McDougle
Journal:  J Autism Dev Disord       Date:  2015-06

5.  Medication-induced acute dystonic reaction: the challenge of diagnosing movement disorders in the intensive care unit.

Authors:  Geneviève Digby; Shirin Jalini; Sean Taylor
Journal:  BMJ Case Rep       Date:  2015-09-21

6.  Comparative analysis of the treatment of chronic antipsychotic drugs on epileptic susceptibility in genetically epilepsy-prone rats.

Authors:  Rita Citraro; Antonio Leo; Rossana Aiello; Michela Pugliese; Emilio Russo; Giovambattista De Sarro
Journal:  Neurotherapeutics       Date:  2015-01       Impact factor: 7.620

Review 7.  Guide to anaesthetic selection for electroconvulsive therapy.

Authors:  Klaus J Wagner; Oliver Möllenberg; Michael Rentrop; Christian Werner; Eberhard F Kochs
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 8.  The role of different serotonin receptor subtypes in seizure susceptibility.

Authors:  Mohammad Hadi Gharedaghi; Mohammad Seyedabadi; Jean-Eric Ghia; Ahmad Reza Dehpour; Reza Rahimian
Journal:  Exp Brain Res       Date:  2013-11-14       Impact factor: 1.972

9.  Severe Ecstasy poisoning in an 8-month-old infant.

Authors:  Frank Eifinger; Bernhard Roth; Lars Kröner; Markus A Rothschild
Journal:  Eur J Pediatr       Date:  2007-09-26       Impact factor: 3.183

Review 10.  Adverse effects of atypical antipsychotics : differential risk and clinical implications.

Authors:  Peter M Haddad; Sonu G Sharma
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.